Neurology Condition Articles & Analysis

Research team AIN-Rehab in collaboration with The University of Newcastle, Australia now has ethics approval to expand the HELLEN research trial using REX to include people living with Multiple Sclerosis. AIN-Rehab continue to work towards the goal of expanding research into the merits of REX for all neurological conditions. ...

By Rex Bionics Ltd

SEATTLE – Aug. 11, 2015 Cadence BiomedicalTM, maker of the Kickstart® which helps people with neurological conditions recover to walking, today announced that its research collaborators from the Université de Montréal and the Center for Interdisciplinary Research in Rehabilitation of Greater Montreal have secured a grant from the Physiotherapy Foundation of Canada and the ...

By Cadence Biomedical

Seattle, WA – June 24, 2015 – Cadence Biomedical, the manufacturers of Kickstart®, designed to enable walking and accelerate therapeutic outcomes for stroke and other neurological conditions, today announced the close of a $1.2M Series B investment round. The round was led by HealthTech Capital and included participation from BioPacific Investments, Frontier Angel Fund, and ...

By Cadence Biomedical

SEATTLE – Oct. 5, 2015 – Today Cadence Biomedical, maker of Kickstart®, which helps people with neurological conditions recover to walking, announced a new research collaboration with the University of Nebraska Omaha (UNO) to study stroke survivors’ ability to adapt and improve motor skills after using the Kickstart device. Dr. Mukul Mukherjee, assistant professor at UNO and ...

By Cadence Biomedical

Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will present an overview of the company and take part in one-on-one meetings with institutional investors at the Jefferies Microbiome-based ...

By Axial Therapeutics Inc.

SEATTLE – Today Cadence Biomedical™, maker of the Kickstart® device, which helps people with neurological conditions recover and walk again, announced its first peer-reviewed publication, “Mobility Training for Patients Recovering from Neurological Injuries with Kickstart®: A Case Series.” The study, published in Physical Medicine and Rehabilitation International, ...

By Cadence Biomedical

BOSTON--(BUSINESS WIRE)-- BIONIK Laboratories Corp. (OTCQB: BNKL) ("BIONIK" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced its participation in the American Physical Therapy Association (APTA) Conference in San Antonio, Texas from February ...

By Bionik

Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will participate in a panel titled “Placing Patients At The Center” at the Longwood Healthcare Leaders Spring MIT webconference ...

By Axial Therapeutics Inc.

CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare ...

By CanaQuest Medical Corp.

Study adds to growing evidence for how gut microbiome impacts Central Nervous System (CNS) function and behavior in mice Research offers valuable mechanistic insights for understanding the potential role of microbial metabolites in neurodevelopmental disorders Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological ...

By Axial Therapeutics Inc.

CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced Statistically Significant efficacy results from the Clinical Dose & Efficacy Study ("Study") conducted by Dr. W McIntyre Burnham, ...

By CanaQuest Medical Corp.

Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company and AB Medica Deutschland Verwaltungs GmbH, a wholly owned subsidiary of Balt, today announced that they have entered into a strategic distribution agreement providing AB Medica with the exclusive rights to market and sell the newly CE marked Contour Neurovascular System™ and the Neqstent Coil Assisted Flow ...

By Cerus Endovascular Inc.

More than 250,000 people are living with epilepsy in Australia, of which 1 in 7 are having difficult-to-notice absence seizures. Such seizures are different from tonic-clonic (convulsive) seizures, and are typically shorter in length, with a brief loss of consciousness. Even though this type of seizure usually does not lead to physical injury, it has a major impact on the wellbeing of the person ...

By Epihunter NV

Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company, today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Contour Neurovascular System™. Breakthrough Device Designation is granted to medical devices and device-led combination products that provide the potential for a more effective ...

By Cerus Endovascular Inc.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will be conducting one-on-ones at the Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum. Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum Date: Thursday, November ...

By electroCore, Inc.

Surgeons at Intermountain Primary Children’s Hospital are the first in the nation to successfully implant a new brain shunt accessory for young patients with hydrocephalus, a neurological condition that causes a buildup of cerebrospinal fluid in the deep cavities of the brain that often causes frequent hospitalizations. This extra fluid puts pressure on the brain and can cause brain ...

By Anuncia Medical, Inc.

Cerus Endovascular Ltd., a privately held, commercial stage medical device company, today announced that it has received CE Mark approval for its 021 Contour Neurovascular System, compatible with smaller commercially available 021 microcatheters for the treatment of saccular intracranial aneurysms. The Contour Neurovascular System is a unique, fine mesh braid that is deployed across the neck of ...

By Cerus Endovascular Inc.

TORONTO & BOSTON--(BUSINESS WIRE)-- BIONIK Laboratories Corp. (OTCQB: BNKL) ("BIONIK" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced the hiring of a new Regional Sales Director, Tony Bellofatto. Bellofatto is an award-winning Medical ...

By Bionik

Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application to conduct a U.S. trial for the Contour Neurovascular System™, indicated for the treatment of intracranial aneurysms. The IDE approval follows the receipt of Breakthrough ...

By Cerus Endovascular Inc.

NESS ZIONA, ISRAEL, March 3, 2022 – Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, has received a grant from the Israel Innovation Authority (IIA) for a total budget of NIS 10 million ($3.1 million) and a net grant of NIS 4 million ($1.25 million). The funds will be used to advance the filing of an IND ...

By Kadimastem Ltd.